Core Viewpoint - The report highlights that Innovent Biologics (01801) achieved a 38% year-on-year revenue increase to 13 billion RMB, with a net profit of 834 million RMB, marking a return to profitability [1] Financial Performance - Revenue for the last year reached 13 billion RMB, reflecting a 38% increase compared to the previous year [1] - The company reported a net profit of 834 million RMB, indicating a turnaround from previous losses [1] Management Guidance - Management reiterated the sales target of 20 billion RMB for 2027 [1] - Despite recent price adjustments and increased competition, sales of Mazdutide continue to show strong momentum [1] Analyst Adjustments - Citigroup raised the revenue forecasts for the company by 24% and 23% for this year and next year, respectively [1] - Earnings per share estimates were increased by 33% and 5% for the same periods [1] - The target price for the stock was raised from 110 HKD to 115 HKD, maintaining a "Buy" rating [1]

格隆汇3月27日｜花旗发布研报称，信达生物(1801.HK)去年收入同比升38%至130亿元人民币，纯利录 得8.34亿元人民币，同比扭亏为盈。管理阶层重申2027年产品销售额为200亿元人民币指引。管理层指 出，尽管近期价格调整和竞争加剧，但玛仕度肽(mazdutide)销售仍保持良好势头。该行对公司今年和明 年收入上调24%及23%，各年每股盈测分别上调33%及5%，其目标价由110港元上调至115港元，维持其 评级为"买入"。 ...